Under the Microscope: Gene Yeo on RNA-Directed Therapy for ALS Caused by a C9ORF72 Mutation

by Steve Schonberg | Oct 11, 2021 | Hear From the Scientists

Throughout the ALS research community, you’ll find brilliant scientists working tirelessly on promising breakthroughs. In our Under the Microscope series, we are shining a light on some of these scientists leading collaborative projects supported by Target ALS — work...

Case Study: Collaboration Accelerates Potential ALS Treatment

by Target ALS | Oct 19, 2018 | Collaboration

One of the early Target ALS-supported consortia studying C9orf72 ALS put forward the idea that it may be possible to treat ALS by targeting C9orf72 peptides directly. To move this idea forward, Target ALS connected Neurimmune, a biotechnology company with a group of...

Case Study: Consortium Explores KPT-350 as a Potential Treatment for ALS

by Target ALS | Oct 19, 2018 | Hear From the Scientists

The ALS drug KPT-350 was one of the first of a dozen therapeutic options to emerge from the Target ALS Innovation Ecosystem and is now poised for clinical trial thanks to the power of collaboration. Shortly after its launch, Target ALS forged and funded one of the...

Target ALS Providing Critical Tool to Study C9ORF72 Biology

by Target ALS | Jun 21, 2018 | From Our Team

Target ALS announced today that it will make the poly(GP) antibody available to the ALS research community worldwide as part of the Foundation’s commitment to creating shared scientific resources to fast track ALS drug development. Recent scientific breakthroughs have...